ERBB2 and prostate cancer: For example, HER2 is amplified and overexpressed in approximately 15% of breast cancers, as well as some gastric, colon, endometrial, lung, cervix, esophageal and pancreatic cancers [28], and EGFR is activated by mutation in some lung cancers and also overexpressed in many lung, colon, breast, bladder, kidney, lung, and prostate cancers [29-31].